Pfiz­er fields a CRL for a $295M rare dis­ease play, giv­ing ri­val a big head start

Pfiz­er won’t be adding a new rare dis­ease drug to the fran­chise club — for now, any­way.

The phar­ma gi­ant put out word that their FDA ap­pli­ca­tion for the growth hor­mone ther­a­py so­ma­tro­gon got the reg­u­la­to­ry heave-ho, though they didn’t even hint at a rea­son for the CRL. Fol­low­ing stan­dard op­er­at­ing pro­ce­dure, Pfiz­er said in a terse mis­sive that they would be work­ing with reg­u­la­tors on a fol­lowup.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER